Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine
Urine toxicology test to monitor medication compliances and detect undisclosed drug/substance use to support pain management, substance use disorders treatment, and other pharmacotherapies involving controlled substances. Testing is qualitative and uses a combination of mass spectrometry as well as immunoassays with documented low false positive rates.
Secondary testing is generally not indicated but is available if confirmation or quantitation is desired. If interpretation is required, refer to Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288). For a traditional screen with reflex to confirmation/quantitation testing, refer to Drug Profile, Screen with Reflex to Quantitation (2012312).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Qualitative Liquid Chromatography-Tandem Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry
New York DOH Approval Status
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month
Effective February 16, 2021
Drugs covered and range of cutoff concentrations.
Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.
||Range of Cutoff Concentrations
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem
|20 - 60 ng/mL|
|Cannabinoids (11-nor-9-carboxy-THC)||20 ng/mL|
|Ethyl Glucuronide||500 ng/mL|
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol
|Phencyclidine (PCP)||25 ng/mL|
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
80326; 80347; 80364; 80355; 80307 (Alt code: G0481)
|Component Test Code*||Component Chart Name||LOINC|
|2007636||Codeine (cutoff 40 ng/mL)||3507-1|
|2007637||Morphine (cutoff 20 ng/mL)||3830-7|
|2007638||6-acetylmorphine (cutoff 20 ng/mL)||10976-9|
|2007640||Oxycodone (cutoff 40 ng/mL)||10998-3|
|2007641||Noroxycodone (cutoff 100 ng/mL)||61424-8|
|2007642||Oxymorphone (cutoff 40 ng/mL)||11247-4|
|2007643||Noroxymorphone (cutoff 100 ng/mL)||89302-4|
|2007644||Hydrocodone (cutoff 40 ng/mL)||12308-3|
|2007646||Norhydrocodone (cutoff 100 ng/mL)||61421-4|
|2007647||Hydromorphone (cutoff 20 ng/mL)||9834-3|
|2007649||Buprenorphine (cutoff 5 ng/mL)||3414-0|
|2007651||Norbuprenorphine (cutoff 20 ng/mL)||58362-5|
|2007652||Fentanyl (cutoff 2 ng/mL)||11235-9|
|2007653||Norfentanyl (cutoff 2 ng/mL)||43199-9|
|2007654||Meperidine metabolite (cutoff 50 ng/mL)||58388-0|
|2007655||Tapentadol (cutoff 100 ng/mL)||72485-6|
|2007656||Tapentadol-o-Sulf (cutoff 200 ng/mL)||72485-6|
|2007658||Methadone (cutoff 150 ng/mL)||3773-9|
|2007660||Tramadol (cutoff 100 ng/mL)||43219-5|
|2007662||Amphetamine (cutoff 50 ng/mL)||19343-3|
|2007663||Methamphetamine (cutoff 200 ng/mL)||3779-6|
|2007664||MDMA- Ecstasy (cutoff 200 ng/mL)||14267-9|
|2007665||MDA (cutoff 200 ng/mL)||42253-5|
|2007666||MDEA- Eve (cutoff 200 ng/mL)||61048-5|
|2007668||Phentermine (cutoff 100 ng/mL)||3957-8|
|2007670||Benzoylecgonine (cutoff 150 ng/mL)||3393-6|
|2007672||Alprazolam (cutoff 40 ng/mL)||9351-8|
|2007673||Alpha-OH-Alprazolam (cutoff 20 ng/mL)||61036-0|
|2007674||Clonazepam (cutoff 20 ng/mL)||19245-0|
|2007675||7-Aminoclonazepam (cutoff 40 ng/mL)||61030-3|
|2007676||Diazepam (cutoff 50 ng/mL)||3550-1|
|2007677||Nordiazepam (cutoff 50 ng/mL)||3861-2|
|2007678||Oxazepam (cutoff 50 ng/mL)||12361-2|
|2007679||Temazepam (cutoff 50 ng/mL)||61060-0|
|2007680||Lorazepam (cutoff 60 ng/mL)||18187-5|
|2007681||Midazolam (cutoff 20 ng/mL)||19585-9|
|2007682||Zolpidem (cutoff 20 ng/mL)||33338-5|
|2007684||Barbiturates (cutoff 200 ng/mL)||3377-9|
|2007687||Ethyl Glucuronide (cutoff 500 ng/mL)||55349-5|
|2007688||Marijuana Metabolite (cutoff 20 ng/mL)||3435-5|
|2007689||PCP (cutoff 25 ng/mL)||3936-2|
|2007690||Carisoprodol (cut-off 100 ng/mL)||21142-5|
|2007691||Targeted drug profile panel||8251-1|
|2008312||EER Tgt drug prof, MS/EMIT, UR||11526-1|
|2013281||Methylphenidate (cutoff 100 ng/mL)||3808-3|
|3003499||Alpha-OH-Midazolam (cutoff 20 ng/mL)||94108-8|
|3003500||Zolpidem Metabolite (cutoff 100 ng/mL)||94103-9|
|3003501||Gabapentin (cutoff 3,000 ng/mL)||92648-5|
|3003502||Naloxone (cutoff 100 ng/mL)||92649-3|
|3003503||Pregabalin (cutoff 3,000 ng/mL)||92651-9|
- abstinence verification
- addiction management
- Comprehensive hybrid
- drug screen
- high res
- medication adherence
- medication compliance
- Pain management
- prenatal drug screen
- substance use disorder